iX Biopharma Secures China Patent for WaferiX Drug Delivery Technology
Source:

iX Biopharma Ltd

February 8, 2018

Singapore, 8 February 2018iX Biopharma Ltd. (“iX Biopharma” or, together with its subsidiaries, “the Group”) is pleased to announce that it has been granted a patent for its WaferiX drug delivery technology by the People’s Republic of China (Patent No. ZL 2013800602813). The patent, which expires on 11 October 2033, allows iX Biopharma to exclusively use and obtain protection for its
WaferiX drug delivery technology in China.

WaferiX is a fast-dissolving, proprietary wafer formulation that allows pharmacologically active compounds, such as ketamine and sildenafil, to be administered sublingually (i.e., placed under the tongue) and delivered safely, conveniently and rapidly into the blood stream. The technology offers a non-invasive, pain-free alternative to traditional routes of drug administration such as intravenous drips and injections. Key advantages of WaferiX include the reduction of the effect of first-pass metabolism, rapid onset of action, better side effect profile, easy administration, improved patient compliance and a better storage profile.

The Group leverages WaferiX to develop a host of innovative pharmaceutical and nutraceutical products, including Wafermine, its lead pain management product.

With the receipt of this China patent, iX Biopharma’s intellectual property rights for its sublingual technology is now secured in key Asian markets, including Singapore, South Korea, Malaysia, Indonesia and Japan.

Apart from Asia, iX Biopharma has also been awarded patents in 20 other countries, namely Australia, New Zealand, Canada, South Africa and countries in the European Union such as Germany, France, United Kingdom, Italy, Spain, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, Austria, Norway, Denmark, Ireland, as well as Finland.

The protection accorded by the patents in the European Union and major Asian markets gives iX Biopharma greater confidence to partner healthcare and skincare companies through out-licensing
arrangements. On 4 January 2018, the Group entered into its first out-licensing agreement with ASX-listed Bod Australia Limited, under which the Group licensed its WaferiX technology for the development of medicinal cannabis products incorporating cannabis extracts provided by Bod, for use in Bod’s Phase 1 clinical trials this year.

The Group will retain all manufacturing rights and intellectual property developed under the agreement apart from the name and rights to the packaging of the finished product. This arrangement timeously coincides with the Australian government’s announcement in January 2018 to legalise the export of medicinal cannabis products, subject to approval by the federal parliament in February 2018.

The agreement is a stepping stone for iX Biopharma to capitalise on the largely untapped and expanding medicinal cannabis market that is set to reach US$55 billion by 2025, according to a report by US-based Grand View Research. The demand is driven by growing recognition among academic researchers and healthcare providers of the numerous therapeutic uses of cannabis, which include pain management and the treatment of epilepsy and multiple sclerosis.

Meanwhile, iX Biopharma will continue to leverage the WaferiX technology to develop its own portfolio of innovative therapies, as well as seek out opportunities to work with other potential partners on out-licensing of the sublingual technology.

Post a Comment

You must be logged in to post a Comment.

FEEDBACK